FDA Approves ImageChecker Computer System

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 8
Volume 7
Issue 8

ROCKVILLE, Md--The FDA has approved a new computer system, the M1000 ImageChecker, made by R2 Technology, Inc., Los Altos, California, to aid radiologists in reviewing mammograms. Studies show that use of the device improved the radiologists’ detection rate from approximately 80 out of 100 cancers to almost 88 out of 100.

ROCKVILLE, Md--The FDA has approved a new computer system, the M1000 ImageChecker, made by R2 Technology, Inc., Los Altos, California, to aid radiologists in reviewing mammograms. Studies show that use of the device improved the radiologists’ detection rate from approximately 80 out of 100 cancers to almost 88 out of 100.

ImageChecker uses a laser beam to convert the mammographic image into a digital signal. The signal is processed in a high-speed computer to identify suspicious areas, which are then highlighted with markers on a video display of the mammographic image. The radiologist, who has already reviewed the mammo-gram in the conventional manner, then looks at the suspicious areas highlighted by ImageChecker and reviews those same areas on the original mammogram to see if any escaped notice, and, if so, whether they require further evaluation.

FDA’s approval of ImageChecker was based on data from clinical studies and the recommendation of the Radiological Devices Panel of FDA’s Medical Devices Advisory Committee.

Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content